{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:59:31Z","timestamp":1790477971895,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The mechanisms of benefit of mineralocorticoid receptors antagonists in congestive heart failure (CHF) are still debated. We hypothesized that aldosterone contributes to pulmonary remodelling and right ventricular (RV) dysfunction associated with CHF by stimulation of lung myofibroblasts (MYFs) proliferation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Rats with moderate to large myocardial infarcts (MI) and CHF were studied. Two weeks after MI, spironolactone 100 mg\/kg\/day (n = 21) or no treatment (n = 24) were given for 3 weeks and compared to sham (n = 8).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Infarct size was similar by ultrasound and pathologic measures in both MI groups.<\/jats:p>\n            <jats:p>The MI-untreated group developed important lung remodelling with nearly doubling of dry lung weight (p &lt; 0.01), reduced left ventricular (LV) fractional shortening (16 \u00b1 2% vs. 53 \u00b1 1%; mean \u00b1 SEM, p &lt; 0.0001), pulmonary hypertension (RV systolic pressure: 40 \u00b1 3 mmHg vs. 27 \u00b1 1 mmHg, p &lt; 0.01) and RV hypertrophy (RV\/(LV + septum): 38 \u00b1 3% vs. 24 \u00b1 1%, p &lt; 0.05). Spironolactone had no effect on these parameters and did not improve LV or RV performance (tricuspid annular plane systolic excursion and RV myocardial performance index) measured by echocardiography. CHF induced a restrictive respiratory syndrome with histological lung fibrosis: this was also unaffected by spironolactone. Finally, isolated lung MYFs did not proliferate after exposure to aldosterone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Aldosterone does not significantly contribute to pulmonary remodelling and RV dysfunction associated with CHF. Other mechanisms are responsible for the beneficial effects of spironolactone in CHF.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2261-11-72","type":"journal-article","created":{"date-parts":[[2011,12,3]],"date-time":"2011-12-03T18:21:01Z","timestamp":1322936461000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure"],"prefix":"10.1186","volume":"11","author":[{"given":"Andreanne","family":"Chabot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao Hua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,2]]},"reference":[{"key":"417_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0735-1097(00)01102-5","volume":"37","author":"S Ghio","year":"2001","unstructured":"Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L: Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001, 37: 183-188. 10.1016\/S0735-1097(00)01102-5.","journal-title":"J Am Coll Cardiol"},{"key":"417_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cardfail.2010.03.003","volume":"16","author":"BH Jiang","year":"2010","unstructured":"Jiang BH, Tardif JC, Sauvageau S, Ducharme A, Shi Y, Martin JG, Dupuis J: Beneficial effects of atorvastatin on lung structural remodeling and function in ischemic heart failure. J Card Fail. 2010, 16: 679-688. 10.1016\/j.cardfail.2010.03.003.","journal-title":"J Card Fail"},{"key":"417_CR3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0008-6363(03)00290-6","volume":"58","author":"JF Jasmin","year":"2003","unstructured":"Jasmin JF, Calderone A, Leung TK, Villeneuve L, Dupuis J: Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. Cardiovasc Res. 2003, 58: 621-631. 10.1016\/S0008-6363(03)00290-6.","journal-title":"Cardiovasc Res"},{"key":"417_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1139\/Y08-024","volume":"86","author":"A Prefontaine","year":"2008","unstructured":"Prefontaine A, Calderone A, Dupuis J: Role of endothelin receptors on basal and endothelin-1-stimulated lung myofibroblast proliferation. Can J Physiol Pharmacol. 2008, 86: 337-342. 10.1139\/Y08-024.","journal-title":"Can J Physiol Pharmacol"},{"key":"417_CR5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00395-003-0419-6","volume":"98","author":"MP Kingsbury","year":"2003","unstructured":"Kingsbury MP, Huang W, Donnelly JL, Jackson E, Needham E, Turner MA, Sheridan DJ: Structural remodelling of lungs in chronic heart failure. Basic Res Cardiol. 2003, 98: 295-303. 10.1007\/s00395-003-0419-6.","journal-title":"Basic Res Cardiol"},{"key":"417_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1378\/chest.125.2.669","volume":"125","author":"BK Gehlbach","year":"2004","unstructured":"Gehlbach BK, Geppert E: The pulmonary manifestations of left heart failure. Chest. 2004, 125: 669-682. 10.1378\/chest.125.2.669.","journal-title":"Chest"},{"key":"417_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1183\/09031936.00053710","volume":"37","author":"BH Jiang","year":"2011","unstructured":"Jiang BH, Tardif JC, Shi Y, Dupuis J: Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure. Eur Respir J. 2011, 37: 578-586. 10.1183\/09031936.00053710.","journal-title":"Eur Respir J"},{"key":"417_CR8","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/S0954-6111(98)90136-6","volume":"92","author":"I Dimopoulou","year":"1998","unstructured":"Dimopoulou I, Daganou M, Tsintzas OK, Tzelepis GE: Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med. 1998, 92: 1321-1325. 10.1016\/S0954-6111(98)90136-6.","journal-title":"Respir Med"},{"key":"417_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999, 341: 709-717. 10.1056\/NEJM199909023411001.","journal-title":"N Engl J Med"},{"key":"417_CR10","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003, 348: 1309-1321. 10.1056\/NEJMoa030207.","journal-title":"N Engl J Med"},{"key":"417_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011, 364: 11-21. 10.1056\/NEJMoa1009492.","journal-title":"N Engl J Med"},{"key":"417_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","volume":"53","author":"SA Hunt","year":"2009","unstructured":"Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW: Focused update incorporated into the ACC\/AHA 2005 guidelines for the diagnosis and management of heart failure in adults a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009, 53: e1-e90. 10.1016\/j.jacc.2008.11.013.","journal-title":"J Am Coll Cardiol"},{"key":"417_CR13","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1001\/jama.2009.1493","volume":"302","author":"NM Albert","year":"2009","unstructured":"Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC: Use of aldosterone antagonists in heart failure. JAMA. 2009, 302: 1658-1665. 10.1001\/jama.2009.1493.","journal-title":"JAMA"},{"key":"417_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/hy1101.099484","volume":"38","author":"F Zannad","year":"2001","unstructured":"Zannad F, Dousset B, Alla F: Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension. 2001, 38: 1227-1232. 10.1161\/hy1101.099484.","journal-title":"Hypertension"},{"key":"417_CR15","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1161\/01.CIR.99.20.2694","volume":"99","author":"JS Silvestre","year":"1999","unstructured":"Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, Swynghedauw B, Delcayre C: Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation. 1999, 99: 2694-2701.","journal-title":"Circulation"},{"key":"417_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/eurheartj\/ehi023","volume":"26","author":"P Agostoni","year":"2005","unstructured":"Agostoni P, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M, Cattadori G, Palermo P: Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J. 2005, 26: 159-164.","journal-title":"Eur Heart J"},{"key":"417_CR17","first-page":"300","volume":"21","author":"L Zhao","year":"1998","unstructured":"Zhao L, Zhao M, Fang Q: Spironolactone ameliorates rat pulmonary fibrosis induced by Sbleomycin a5. Zhonghua Jie He He Hu Xi Za Zhi. 1998, 21: 300-302.","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"417_CR18","volume-title":"Guide for the care and use of laboratory animals","author":"Institute of Laboratory Animal Research CoLS","year":"1996","unstructured":"Institute of Laboratory Animal Research CoLS, National Research Council: Guide for the care and use of laboratory animals. 1996, Washington D.C.: National Academy Press"},{"key":"417_CR19","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.carpath.2010.04.005","volume":"20","author":"BH Jiang","year":"2011","unstructured":"Jiang BH, Nguyen QT, Tardif JC, Shi Y, Dupuis J: Single measurement of troponin T for early prediction of infarct size, congestive heart failure, and pulmonary hypertension in an animal model of myocardial infarction. Cardiovasc Pathol. 2011, 20: e85-89. 10.1016\/j.carpath.2010.04.005.","journal-title":"Cardiovasc Pathol"},{"key":"417_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1042\/CS20060027","volume":"111","author":"F Lefebvre","year":"2006","unstructured":"Lefebvre F, Prefontaine A, Calderone A, Caron A, Jasmin JF, Villeneuve L, Dupuis J: Modification of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure. Clin Sci (Lond). 2006, 111: 217-224. 10.1042\/CS20060027.","journal-title":"Clin Sci (Lond)"},{"key":"417_CR21","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/sj.bjp.0703466","volume":"130","author":"QT Nguyen","year":"2000","unstructured":"Nguyen QT, Colombo F, Rouleau JL, Dupuis J, Calderone A: Lu135252, an endothelin(A) receptor antagonist did not prevent pulmonary vascular remodelling or lung fibrosis in a rat model of myocardial infarction. Br J Pharmacol. 2000, 130: 1525-1530. 10.1038\/sj.bjp.0703466.","journal-title":"Br J Pharmacol"},{"key":"417_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.cardiores.2004.08.004","volume":"64","author":"A Lal","year":"2004","unstructured":"Lal A, Veinot JP, Leenen FH: Critical role of CNS effects of aldosterone in cardiac remodeling post-myocardial infarction in rats. Cardiovasc Res. 2004, 64: 437-447. 10.1016\/j.cardiores.2004.08.004.","journal-title":"Cardiovasc Res"},{"key":"417_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1291\/hypres.30.427","volume":"30","author":"M Takeda","year":"2007","unstructured":"Takeda M, Tatsumi T, Matsunaga S, Hayashi H, Kimata M, Honsho S, Nishikawa S, Mano A, Shiraishi J, Yamada H, Takahashi T, Matoba S, Kobara M, Matsubara H: Spironolactone modulates expressions of cardiac mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase 2 and prevents ventricular remodeling in post-infarct rat hearts. Hypertens Res. 2007, 30: 427-437. 10.1291\/hypres.30.427.","journal-title":"Hypertens Res"},{"key":"417_CR24","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1046\/j.1440-1681.2003.03906.x","volume":"30","author":"JG Mill","year":"2003","unstructured":"Mill JG, Milanez Mda C, de Resende MM, Gomes Mda G, Leite CM: Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats. Clin Exp Pharmacol Physiol. 2003, 30: 739-744. 10.1046\/j.1440-1681.2003.03906.x.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"417_CR25","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","volume":"29","author":"P Mulder","year":"2008","unstructured":"Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, Richard V, Henry JP, Jeng AY, Webb RL, Thuillez C: Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J. 2008, 29: 2171-2179. 10.1093\/eurheartj\/ehn277.","journal-title":"Eur Heart J"},{"key":"417_CR26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1359-6101(03)00055-8","volume":"14","author":"A O'Regan","year":"2003","unstructured":"O'Regan A: The role of osteopontin in lung disease. Cytokine Growth Factor Rev. 2003, 14: 479-488. 10.1016\/S1359-6101(03)00055-8.","journal-title":"Cytokine Growth Factor Rev"},{"key":"417_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1161\/CIRCRESAHA.107.160408","volume":"102","author":"Y Lenga","year":"2008","unstructured":"Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R: Osteopontin expression is required for myofibroblast differentiation. Circ Res. 2008, 102: 319-327. 10.1161\/CIRCRESAHA.107.160408.","journal-title":"Circ Res"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2261-11-72.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2261-11-72\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2261-11-72","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2261-11-72.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T18:30:27Z","timestamp":1630521027000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/1471-2261-11-72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1186\/1471-2261-11-72","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"20 September 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"72"}}